Clear Harbor Asset Management LLC Has $288,000 Stock Position in Arbutus Biopharma Co. (NASDAQ:ABUS)

Clear Harbor Asset Management LLC lessened its stake in Arbutus Biopharma Co. (NASDAQ:ABUS) by 25.8% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 74,761 shares of the biopharmaceutical company’s stock after selling 26,000 shares during the quarter. Clear Harbor Asset Management LLC’s holdings in Arbutus Biopharma were worth $288,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Susquehanna Fundamental Investments LLC acquired a new position in shares of Arbutus Biopharma in the 1st quarter valued at approximately $266,000. BNP Paribas Financial Markets raised its position in Arbutus Biopharma by 19.7% during the first quarter. BNP Paribas Financial Markets now owns 349,435 shares of the biopharmaceutical company’s stock valued at $902,000 after purchasing an additional 57,390 shares in the last quarter. Rubric Capital Management LP bought a new stake in Arbutus Biopharma during the second quarter worth $5,195,000. Kennedy Capital Management LLC boosted its holdings in shares of Arbutus Biopharma by 12.7% in the 1st quarter. Kennedy Capital Management LLC now owns 436,506 shares of the biopharmaceutical company’s stock valued at $1,126,000 after purchasing an additional 49,265 shares in the last quarter. Finally, Walleye Trading LLC bought a new position in shares of Arbutus Biopharma in the 1st quarter valued at $36,000. Institutional investors own 43.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ABUS. Jefferies Financial Group upped their price objective on Arbutus Biopharma from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th. StockNews.com upgraded shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 10th. Finally, JMP Securities upped their price objective on shares of Arbutus Biopharma from $4.00 to $5.00 and gave the stock a “market outperform” rating in a research report on Friday, August 2nd. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $5.25.

Arbutus Biopharma Trading Down 2.0 %

Arbutus Biopharma stock opened at $3.97 on Monday. The stock has a 50-day moving average price of $4.02 and a two-hundred day moving average price of $3.51. Arbutus Biopharma Co. has a 12 month low of $1.70 and a 12 month high of $4.72.

Arbutus Biopharma (NASDAQ:ABUS) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Arbutus Biopharma had a negative net margin of 766.20% and a negative return on equity of 66.68%. The business had revenue of $1.73 million during the quarter, compared to the consensus estimate of $1.54 million. During the same quarter last year, the business earned ($0.10) EPS. As a group, equities analysts predict that Arbutus Biopharma Co. will post -0.38 earnings per share for the current fiscal year.

Arbutus Biopharma Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.